Sugi Predict

Sugi Predict / Compounds / Aletamine

Aletamine

Aletamine

SCHEMBL122065

C=CCC(N)Cc1ccccc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.64
▸ ANPEP P15144 2/20 0.55
▸ SLC6A2 P23975 2/20 0.48
▸ TAAR1 Q96RJ0 2/20 0.48
▸ MAOA P21397 1/20 0.48
▸ SLC6A4 P31645 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ SIGMAR1 Q99720 1/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ ADORA2A P29274 1/20 0.48
▸ ADORA1 P30542 1/20 0.48
▸ CYP2D6 P10635 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ALPI P09923 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ XIAP P98170 1/20 0.44
▸ SLC7A5 Q01650 1/20 0.44
▸ SCN4A P35499 2/20 0.42
▸ MMP2 P08253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aletamine SCHEMBL5038065 1.00 EPHX1 (0.64) EPHX1ANPEPSLC6A2TAAR1MAOA
Aletamine SCHEMBL122064 0.98 EPHX1 (0.61) EPHX1ANPEPSLC6A2TAAR1MAOA
SCHEMBL5036906 0.80 SLC6A4 (0.67) EPHX1ANPEPSLC6A2TAAR1SLC6A4
SCHEMBL3753234 0.80 ANPEP (0.44) EPHX1ANPEPTAAR1MAOACYP2A6
SCHEMBL10570621 0.80 ANPEP (0.44) EPHX1ANPEPTAAR1MAOACYP2A6
SCHEMBL9203453 0.80 SLC6A4 (0.67) EPHX1ANPEPSLC6A2TAAR1SLC6A4
SCHEMBL28656 0.79 EPHX1 (1.00) EPHX1ANPEPSLC6A2TAAR1MAOA
SCHEMBL11947633 0.79 EPHX1 (0.64) EPHX1ANPEPSLC6A2TAAR1MAOA
SCHEMBL5159235 0.79 EPHX1 (0.46) EPHX1ANPEPSLC6A2TAAR1MAOA
SCHEMBL4975192 0.79 EPHX1 (0.64) EPHX1ANPEPSLC6A2TAAR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 — — EP claimed
EP-1960350-B1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER IP GMBH (DE) 2015-08-19 — — EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 — — WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 — — US claimed
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 — — US claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 — — US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-6927036-B2 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XERO PORT, INC. (US) 2005-08-09 — — US claimed
US-20040254182-A1 Enhanced propertied pharmaceuticals ROHM AND HAAS COMPANY 2004-12-16 — — US claimed
EP-1272463-A1 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2003-01-08 — — EP claimed
WO-2001054481-A2 ENHANCED PROPERTIED PHARMACEUTICALS ROHM AND HAAS COMPANY (US) 2001-08-02 — — WO claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 — — WO claimed
US-5684018-A Acyloxyisopropyl carbamates as prodrugs for amine drugs MERCK & CO., INC. (US) 1997-11-04 — — US claimed
WO-1996018605-A1 ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS MERCK & CO., INC. (US) 1996-06-20 — — WO claimed
EP-0174342-B1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1989-12-20 — — EP claimed
EP-0174342-A1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. UNIV FLORIDA (US) 1986-03-19 — — EP claimed
WO-1985003937-A1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1985-09-12 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254182-A1 Enhanced propertied pharmaceuticals ABCB1, ABCB11, ABCG2 EPHX1 1425/4885ANPEP 347/4885SLC6A2 129/4885
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA EPHX1 2516/4885ANPEP 504/4885SLC6A2 999/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA EPHX1 2516/4885ANPEP 504/4885SLC6A2 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.